Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aleniglipron in Obesity or Overweight with Comorbidities (ACCESS II)
NCT06703021Phase 2Completed
- Sponsor
- Gasherbrum Bio
- Start
- Dec 2024
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of aleniglipron in obesity (4 arms), sponsored by Gasherbrum Bio. Primary endpoints: Treatment-emergent adverse events and serious adverse events at 44 weeks, Adverse events of special interest at 44 weeks and 3 more. Started Dec 2024; status: completed.
02
Drugs
aleniglipron
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06703021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06703021.